.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Susana Banerjee

Articles

Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201

December 17th 2024

Professor Susana Banerjee presents the ENGOT-OV60/GOG-3052/RAMP 201 study, highlighting the efficacy and safety of avutometinib ± defactinib in recurrent low-grade serous ovarian cancer.